Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Zsofia Kinga Stadler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6985-2864; OpenAlex author ID A5074087271. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 12

  1. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  2. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s40291-022-00614-1↗
  3. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. Co-author DOI 10.1001/jamaoncol.2019.5963↗
  4. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Co-author DOI 10.1158/1940-6207.capr-18-0272↗
  5. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  6. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  7. Acquired resistance to immunotherapy in MMR-D pancreatic cancer. Co-author DOI 10.1186/s40425-018-0448-1↗
  8. Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma? First author DOI 10.1200/po.17.00227↗
  9. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Co-author DOI 10.1586/17474124.2016.1153424↗
  10. Identification of germline genetic mutations in patients with pancreatic cancer. Last author DOI 10.1002/cncr.29664↗
  11. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Co-author DOI 10.1002/cncr.26191↗
  12. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Co-author DOI 10.1634/theoncologist.2011-0185↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 9 shared papers, 2011–2025 · strength 0.78
  2. Erin E. Salo‐Mullen · 8 shared papers, 2011–2020 · strength 0.52
  3. Kenneth H. Yu · 6 shared papers, 2011–2025 · strength 0.48
  4. David Paul Kelsen · 7 shared papers, 2011–2025 · strength 0.46
  5. Marinela Capanu · 4 shared papers, 2018–2025 · strength 0.42
  6. Anna M. Varghese · 3 shared papers, 2018–2025 · strength 0.36
  7. Christine A. Iacobuzio–Donahue · 3 shared papers, 2016–2025 · strength 0.30
  8. Wungki Park · 2 shared papers, 2022–2025 · strength 0.29
  9. Michael Rainone · 2 shared papers, 2020–2022 · strength 0.26
  10. Maeve Aine Lowery · 5 shared papers, 2011–2018 · strength 0.26
  11. Robert C. Kurtz · 4 shared papers, 2011–2019 · strength 0.18
  12. Olca Baştürk · 1 shared paper, 2025 · strength 0.17
  13. William R. Jarnagin · 1 shared paper, 2025 · strength 0.17
  14. Fiyinfolu O. Balogun · 1 shared paper, 2025 · strength 0.17
  15. Alice Chia-Chi Wei · 1 shared paper, 2025 · strength 0.17
  16. Mark Andrew Schattner · 1 shared paper, 2025 · strength 0.17
  17. Alicia J. Latham · 1 shared paper, 2018 · strength 0.17
  18. Zishuo I. Hu · 2 shared papers, 2018 · strength 0.15
  19. Luis Alberto Diaz · 2 shared papers, 2018 · strength 0.15
  20. Isha Singh · 1 shared paper, 2020 · strength 0.15
  21. İbrahim Halil Şahin · 2 shared papers, 2016–2018 · strength 0.13
  22. Amethyst Saldia · 2 shared papers, 2015–2019 · strength 0.13
  23. Binbin Zheng-Lin · 1 shared paper, 2022 · strength 0.12
  24. Leonard B. Saltz · 2 shared papers, 2015–2018 · strength 0.10
  25. Andrew S. Epstein · 2 shared papers, 2015–2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.